Results 81 to 90 of about 286 (123)

[Long-term outcomes of maxillectomy for paranasal sinus cancer]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc
Ramírez-Echavarría A   +4 more
europepmc   +1 more source

[Neuroendocrine expression markers in triple-negative, luminal-A, luminal-B and HER2neu breast cancer]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc
Barboza-García YG   +4 more
europepmc   +1 more source

[Pattern of invasive growth of pituitary adenomas with positive hormonal immunohistochemistry]. [PDF]

open access: yesRev Med Inst Mex Seguro Soc
Bello-Lemus VH   +2 more
europepmc   +1 more source

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). [PDF]

open access: yesJ Clin Oncol
Garcia-Carbonero R   +24 more
europepmc   +1 more source

[Solid Pseudopapillary Neoplasm of the Pancreas: Diagnosis and Surgical Management in a Young Patient]. [PDF]

open access: yesActa Gastroenterol Latinoam
García Alba EL   +6 more
europepmc   +1 more source

Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914). [PDF]

open access: yesClin Cancer Res
Capdevila J   +19 more
europepmc   +1 more source

Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

open access: yesEndocr Rev, 2023
Garcia-Carbonero R   +7 more
europepmc   +1 more source

Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial. [PDF]

open access: yesNat Commun
Capdevila J   +23 more
europepmc   +1 more source

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. [PDF]

open access: yesESMO Open
Capdevila J   +41 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy